The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2013.11.016 ◽

2014 ◽

Vol 132 (3) ◽

pp. 560-565 ◽

Author(s):

Amanda Nickles Fader ◽

James Java ◽

Thomas C. Krivak ◽

Robert E. Bristow ◽

Ana I. Tergas ◽

...

Keyword(s):

Ovarian Carcinoma ◽

Gynecologic Oncology ◽

Prognostic Significance ◽

Post Treatment ◽

Ca 125 ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Serous Ovarian Carcinoma

Download Full-text

The prognostic significance of pre and post-treatment CA-125 levels in low grade serous ovarian carcinoma: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.12.081 ◽

2012 ◽

Vol 125 ◽

pp. S35-S36

Author(s):

A. Nickles Fader ◽

J. Java ◽

A. Tergas ◽

T. Krivak ◽

R. Bristow ◽

...

Keyword(s):

Ovarian Carcinoma ◽

Gynecologic Oncology ◽

Prognostic Significance ◽

Post Treatment ◽

Ca 125 ◽

Low Grade ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Serous Ovarian Carcinoma

Download Full-text

The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1)

Gynecologic Oncology ◽

10.1016/j.ygyno.2019.02.010 ◽

2019 ◽

Vol 153 (2) ◽

pp. 312-319

Author(s):

Ryusuke Murakami ◽

Noriomi Matsumura ◽

Hirofumi Michimae ◽

Hiroshi Tanabe ◽

Mayu Yunokawa ◽

...

Keyword(s):

Ovarian Carcinoma ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Mesenchymal Transition ◽

Serous Ovarian Carcinoma ◽

Taxane Chemotherapy

Download Full-text

The prognostic significance of pre-operative vs. prechemotherapy CA-125 in high-risk early-stage epithelial ovarian cancer: A gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2009.10.020 ◽

2010 ◽

Vol 116 (3) ◽

pp. 596

Author(s):

J. Chan ◽

T. Chunqiao ◽

K. Yang ◽

J. Kesterson ◽

B. Monk ◽

...

Keyword(s):

Ovarian Cancer ◽

High Risk ◽

Epithelial Ovarian Cancer ◽

Early Stage ◽

Gynecologic Oncology ◽

Prognostic Significance ◽

Ca 125 ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Download Full-text

Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma—a Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1016/s0090-8258(03)00068-4 ◽

2003 ◽

Vol 89 (1) ◽

pp. 148-154 ◽

Author(s):

Jeffrey D Bloss ◽

Mark F Brady ◽

Shu Yuan Liao ◽

Thomas Rocereto ◽

Edward E Partridge ◽

...

Keyword(s):

Ovarian Carcinoma ◽

Papillary Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Serous Ovarian Carcinoma ◽

Serous Papillary Carcinoma

Download Full-text

Reclassification of Serous Ovarian Carcinoma by a 2-Tier System: A Gynecologic Oncology Group Study

Yearbook of Medicine ◽

10.1016/s0084-3873(12)00204-0 ◽

2012 ◽

Vol 2012 ◽

pp. 140-141

Author(s):

J.T. Thigpen

Keyword(s):

Ovarian Carcinoma ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

System A ◽

Serous Ovarian Carcinoma ◽

Download Full-text

Reclassification of Serous Ovarian Carcinoma by a 2-Tier System: A Gynecologic Oncology Group Study

Yearbook of Oncology ◽

10.1016/j.yonc.2012.08.026 ◽

2012 ◽

Vol 2012 ◽

pp. 119-120

Author(s):

J.T. Thigpen

Keyword(s):

Ovarian Carcinoma ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

System A ◽

Serous Ovarian Carcinoma ◽

Download Full-text

A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.05.029 ◽

2018 ◽

Vol 150 (2) ◽

pp. 247-252 ◽

Author(s):

John K. Chan ◽

William Brady ◽

Bradley J. Monk ◽

Jubilee Brown ◽

Mark S. Shahin ◽

...

Keyword(s):

Ovarian Carcinoma ◽

Phase Ii ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Clear Cell Ovarian Carcinoma

Download Full-text

Optimal cytoreductive surgery to microscopic residual improves survival in women with low grade serous ovarian carcinoma: A Gynecologic Oncology Group ancillary study

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.12.029 ◽

2012 ◽

Vol 125 ◽

pp. S12-S13

Author(s):

A. Nickles Fader ◽

J. Java ◽

S. Ueda ◽

M. Bookman ◽

R. Bristow ◽

...

Keyword(s):

Ovarian Carcinoma ◽

Cytoreductive Surgery ◽

Gynecologic Oncology ◽

Low Grade ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Ancillary Study ◽

Serous Ovarian Carcinoma

Download Full-text

Response to Dr. Markman's letter “Re: ‘Randomized phase III trial of three versus six cycles of carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group Study’”

Gynecologic Oncology ◽

10.1016/j.ygyno.2007.01.007 ◽

2007 ◽

Vol 105 (1) ◽

pp. 280-281

Author(s):

J BELL

Keyword(s):

Ovarian Carcinoma ◽

Early Stage ◽

Gynecologic Oncology ◽

Epithelial Ovarian Carcinoma ◽

Phase Iii ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Phase Iii Trial ◽

Oncology Group Study

Download Full-text

Intraperitoneal Interferon-α in Residual Ovarian Carcinoma: A Phase II Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1006/gyno.1999.5532 ◽

1999 ◽

Vol 75 (1) ◽

pp. 10-14 ◽

Author(s):

Jonathan S. Berek ◽

Maurie Markman ◽

Bette Stonebraker ◽

Samuel S. Lentz ◽

Mark D. Adelson ◽

...

Keyword(s):

Ovarian Carcinoma ◽

Phase Ii ◽

Gynecologic Oncology ◽

Interferon Α ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Download Full-text